Biscone Mark J, Miamidian John L, Muchiri John M, Baik Sarah S W, Lee Fang-Hua, Doms Robert W, Reeves Jacqueline D
Department of Microbiology, University of Pennsylvania, 225 Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, USA.
Virology. 2006 Jul 20;351(1):226-36. doi: 10.1016/j.virol.2006.03.017. Epub 2006 Apr 21.
The bridging sheet region of the gp120 subunit of the HIV-1 Env protein interacts with the major virus coreceptors, CCR5 and CXCR4. We examined the impact of mutations in and adjacent to the bridging sheet region of an X4 tropic HIV-1 on membrane fusion and entry inhibitor susceptibility. When the V3-loop of this Env was changed so that CCR5 was used, the effects of these same mutations on CCR5 use were assayed as well. We found that coreceptor-binding site mutations had greater effects on CXCR4-mediated fusion and infection than when CCR5 was used as a coreceptor, perhaps related to differences in coreceptor affinity. The mutations also reduced use of the alternative coreceptors CCR3 and CCR8 to varying degrees, indicating that the bridging sheet region is important for the efficient utilization of both major and minor HIV coreceptors. As seen before with a primary R5 virus strain, bridging sheet mutations increased susceptibility to the CCR5 inhibitor TAK-779, which correlated with CCR5 binding efficiency. Bridging sheet mutations also conferred increased susceptibility to the CXCR4 ligand AMD-3100 in the context of the X4 tropic Env. However, these mutations had little effect on the rate of membrane fusion and little effect on susceptibility to enfuvirtide, a membrane fusion inhibitor whose activity is dependent in part on the rate of Env-mediated membrane fusion. Thus, mutations that reduce coreceptor binding and enhance susceptibility to coreceptor inhibitors can affect fusion and enfuvirtide susceptibility in an Env context-dependent manner.
HIV-1包膜蛋白gp120亚基的桥接片层区域与主要病毒共受体CCR5和CXCR4相互作用。我们研究了X4嗜性HIV-1桥接片层区域及其邻近区域的突变对膜融合和进入抑制剂敏感性的影响。当改变该包膜蛋白的V3环以使用CCR5时,也检测了这些相同突变对CCR5使用的影响。我们发现,与使用CCR5作为共受体相比,共受体结合位点突变对CXCR4介导的融合和感染的影响更大,这可能与共受体亲和力的差异有关。这些突变还不同程度地降低了对替代共受体CCR3和CCR8的使用,表明桥接片层区域对于HIV主要和次要共受体的有效利用都很重要。如之前在一株原发性R5病毒株中所见,桥接片层突变增加了对CCR5抑制剂TAK-779的敏感性,这与CCR5结合效率相关。在X4嗜性包膜蛋白的背景下,桥接片层突变也使对CXCR4配体AMD-3100的敏感性增加。然而,这些突变对膜融合速率影响很小,对恩夫韦肽(一种膜融合抑制剂,其活性部分取决于包膜蛋白介导的膜融合速率)的敏感性影响也很小。因此,降低共受体结合并增强对共受体抑制剂敏感性的突变可以以包膜蛋白背景依赖的方式影响融合和恩夫韦肽敏感性。